Bioniche Life Sciences Inc. 25 Years
Contact Us Careers
Home Newsroom
In the News

July 29, 2014
Bioniche Announces Submission of Orphan Drug Designation Application for MCNA in the United States

July 18, 2014
Bioniche Announces Intention to File for Marketing Approval of MCNA in the United States

Investors

Latest TSX stock price

All prices delayed at least 15 minutes.
Source: TSX Inc.


Newsroom

 

Bioniche Life Sciences Inc. is a leading clinical stage biotechnology company focused on the development, manufacturing, and commercialization of proprietary and innovative therapeutics for the global human health market. The Company’s anchor product is in Phase III clinical development to treat non-muscle-invasive bladder cancer.

The Company is publicly traded on the Toronto Stock Exchange (TSX: BNC).

The information contained in the Company’s news releases was accurate at the time of posting on this website, but the information may be superseded by subsequent corporate disclosures.

News Releases

To receive our news releases directly, please enter your e-mail address here.

Media Coverage

For recent media coverage of Bioniche Life Sciences Inc. click here >>

Latest News

July 29, 2014
Bioniche Announces Submission of Orphan Drug Designation Application for MCNA in the United States more...

July 18, 2014
Bioniche Announces Intention to File for Marketing Approval of MCNA in the United States more...

June 13, 2014
Bioniche Life Sciences Inc. to Present at Bloom Burton & Co. Healthcare Investor Conference more...

More News

Category: 


Bioniche Key Facts

CEO:
Dr. Michael Berendt

TSX stock symbol:
TSX

Fiscal year-end:
June 30

Headquarters:
Belleville, Ontario

Employees:
50

Focus area:
Human Therapeutics

Copyright 2004, Bioniche Life Sciences Inc. All rights reserved  |  Legal Disclaimer  |  Privacy Policy